Trapped surfaces and the positivity of bondi mass

It is shown that the Bondi Mass of an asymptotically flat space-time which satisfies the dominant energy condition and which contains a number of trapped surfaces is positive

Relative humidity predominantly determines long‐term biocrust‐forming lichen cover in drylands under climate change

1. Manipulative experiments typically show a decrease in dryland biocrust cover and altered species composition under climate change. Biocrust‐forming lichens, such as the globally distributed Diploschistes diacapsis, are particularly affected and show a decrease in cover with simulated climate change. However, the underlying mechanisms are not fully understood, and long‐term interacting effects of different drivers are largely unknown due to the short‐term nature of the experimental studies conducted so far. 2. We addressed this gap and successfully parameterised a process‐based model for D. diacapsis to quantify how changing atmospheric CO2, temperature, rainfall amount and relative humidity affect its photosynthetic activity and cover. We also mimicked a long‐term manipulative climate change experiment to understand the mechanisms underlying observed patterns in the field. 3. The model reproduced observed experimental findings: warming reduced lichen cover, whereas less rainfall had no effect on lichen performance. This warming effect was caused by the associated decrease in relative humidity and non‐rainfall water inputs, which are major water sources for biocrust‐forming lichens. Warming alone, however, increased cover because higher temperatures promoted photosynthesis during early morning hours with high lichen activity. When combined, climate variables showed non‐additive effects on lichen cover, and effects of increased CO2 levelled off with decreasing levels of relative humidity. 4. Synthesis. Our results show that a decrease in relative humidity, rather than an increase in temperature, may be the key factor for the survival of the lichen D. diacapsis under climate change and that effects of increased CO2 levels might be offset by a reduction in non‐rainfall water inputs in the future. Because of a global trend towards warmer and drier air and the widespread global distribution of D. diacapsis, this will affect lichen‐dominated dryland biocrust communities and their role in regulating ecosystem functions worldwide.This research was supported by the Collaborative Research Centre 973 (www.sfb973.de) of the German Research Foundation (DFG) and by the European Research Council (grant agreement no. 647038 (BIODESERT)). P. Porada appreciates funding by Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)—408092731. F.T. Maestre acknowledges support from Generalitat Valenciana (CIDEGENT/2018/041) and the Alexander Von Humboldt Foundation. J. Raggio acknowledges the ERA-Net BiodivERsA program as Soil Crust InterNational (SCIN) and The Spanish Ministerio de Economía y Competitividad (MINECO) project numbers PRI-PIMBDV-2011-0874 and CRYPTOCOVER, CTM2015-64728-C21-R

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo